Losartan Potassium Tablets — Class II drug recall D-0122-2020
Ongoing recall by Torrent Pharma Inc., reported 2019-10-09, distributed nationwide. CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished
| Recall number | D-0122-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Torrent Pharma Inc., Basking Ridge, NJ, United States |
| Recall initiated | 2019-09-19 |
| Classified | 2019-10-02 |
| Reported by FDA | 2019-10-09 |
| Distributed | Nationwide (US) |
| Quantity | 39,432 bottles |
| Reason classes | cgmp, specification failure |
| NDC | 13668-0115-10, 13668-0115-90 |
| Lot numbers | 4DU3D018, 4DU3E009 |
| Expiration dates | 2020-12-31, 2021-02-28 |
Product
Losartan Potassium Tablets, USP 100 mg, [90 or 1000] tablets per bottle, Rx Only, Manufactured for: Torrent Pharma Inc., Basking Ridge, NJ 07920. NDC 90 tablets: 13668-115-90; NDC 1000 tablets: 13668-115-10
Reason for recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0122-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.